Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 71335-2578

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 71335-2578). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alfuzosin Fig1)

Figure 1 (Alfuzosin Fig1)
A line graph showing mean plasma concentration of Alfuzosin over 24 hours after a single 10 mg dose of Alfuzosin Hydrochloride extended-release tablets in healthy middle-aged male volunteers, comparing fed versus fasted states. Concentration (ng/mL) is on the vertical axis and time (hours) on the horizontal axis, with error bars indicating SEM. Fed state shows higher plasma concentration than fasted state over time.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
A line graph depicting mean change from baseline in IPSS Total Symptom Score over 84 days of treatment, comparing Alfuzosin Hydrochloride (10 mg) and placebo groups. The X-axis represents days of treatment (0, 28, 56, 84), and the Y-axis shows mean change, with Alfuzosin Hydrochloride showing a greater decrease than placebo across the timeline.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
A line graph showing the mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing Placebo (N=152) and Alfuzosin Hydrochloride (N=137). The graph indicates a greater reduction in symptom score over time for Alfuzosin Hydrochloride compared to Placebo, with data points at days 0, 28, 56, and 84.*
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
A line graph illustrating mean change from baseline in IPSS total symptom score over 84 days of treatment. The graph compares two groups: placebo (N=150) represented by a dashed line with triangles, and Alfuzosin Hydrochloride (N=151) represented by a solid line with squares. The Alfuzosin Hydrochloride group shows a greater reduction in symptom score than placebo over time.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
A line graph illustrating mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment for two groups: placebo (N=167) and Alfuzosin Hydrochloride (N=170). The x-axis represents days of treatment, and the y-axis represents mean change in mL/s. Data points show notable increase for Alfuzosin Hydrochloride compared to placebo, with statistical significance indicated at day 84.*
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment. Two groups are compared: Placebo and Alfuzosin Hydrochloride, with Alfuzosin showing a greater increase in peak urine flow rate throughout the trial period. The x-axis represents days of treatment, and the y-axis represents mean change in mL/s.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
A line graph comparing mean changes from baseline in peak urine flow rate (mL/s) over 84 days of treatment between a placebo group and an Alfuzosin Hydrochloride group. The x-axis represents days of treatment, and the y-axis shows mean change in mL/s. The graph presents treatment effects over time for both groups.*
FDA Label Image

Chemical Structure (Alfuzosin Str)

Chemical Structure (Alfuzosin Str)
Chemical structure of Alfuzosin Hydrochloride depicted with its molecular atoms and bonds, including the hydroxy and ring components, as well as the hydrochloride moiety indicated by HCl.*
FDA Label Image

Label (Lbl713352578)

Label (Lbl713352578)
Label for Alfuzosin Hydrochloride Extended-Release Tablets USP 10 mg, film-coated tablets, repackaged by Bryant Ranch Prepack, Inc. The label states the product NDC 71335-2578-1 and a quantity of 30 tablets. It includes storage instructions and mentions manufacturing by Aurobindo Pharma Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.